News & Views

Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.

Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50 million.

Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public Offering.

Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology (VisAcT).

Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd (Cyclotek).

Telix is pleased to announce a licence agreement collaboration with Abzena plc (Abzena) for its prostate-specific membrane antigen antibodies (PSMA).

Telix is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS (Atlab).

Telix is pleased to announce a product development partnership with Therapeia GmbH & Co KG (“Therapeia”).